14-day Premium Trial Subscription Try For FreeTry Free
Immutep reports enrollment completed for INSIGHT-004 study IMMP MKGAY PFE
Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...

Enrollment completed for the INSIGHT-004 Study

12:17am, Wednesday, 22'nd Apr 2020
SYDNEY, Australia, April 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.

Immutep Advances Cell Line Development for IMP761

01:35am, Thursday, 16'th Apr 2020
SYDNEY, Australia, April 16, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing.

MT, SSL among premarket losers

01:16pm, Wednesday, 15'th Apr 2020
Obalon Therapeutics (NASDAQ:OBLN) -25%.NeuroMetrix (NASDAQ:NURO) -16%.Cocrystal Pharma (NASDAQ:COCP) -14%.Covanta Holding (NYSE:CVA) -12% on dividend cut and guidance pull.Independence Contract Dri
SYDNEY, Australia, April 14, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plan
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord
Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmarkIncreased Overall Response Rate (ORR) of 48.3%.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the o
Even if it's not a huge purchase, we think it was good to see that Grant Chamberlain, the Non-Executive Director of...
Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancerAIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09,.

Immutep Reports Positive TACTI-002 Data

01:00pm, Wednesday, 19'th Feb 2020
Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE